GlassScriptPhysician profile
Morgan Nelson
NPI 1093106510
$5,515.05
in general payments reported to CMS, 2019-2025
32 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $756 · 2023: $919 · 2024: $1,651 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,308.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,293.92 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,155.31 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $601.17 | 2022-2025 | Tremfya, Stelara, Remicade |
| Phathom Pharmaceuticals, INC. | $355.19 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $280.84 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $257.85 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $160.37 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $150.21 | 2022-2024 | Linzess |
| Lilly USA, LLC | $148.60 | 2021-2025 | Omvoh |
| Genzyme Corporation | $117.71 | 2023-2025 | |
| Pfizer INC. | $105.27 | 2023-2025 | |
| Celltrion USA INC. | $96.56 | 2024-2025 | Vegzelma |
| Amarin Pharma, INC. | $74.97 | 2021 | |
| Aimmune Therapeutics, INC. | $74.12 | 2024-2025 | Vowst |
| Madrigal Pharmaceuticals | $73.15 | 2025 | Rezdiffra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocon Biologics INC | $59.30 | 2025 | Yesintek |
| Glaxosmithkline, LLC. | $56.85 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $54.18 | 2021 | |
| Celgene Corporation | $51.00 | 2023-2024 | Zeposia |
| Boston Scientific Corporation | $47.37 | 2022 | |
| Braintree Laboratories, INC. | $45.34 | 2022-2025 | Suflave, Sutab |
| Novo Nordisk INC | $43.49 | 2021-2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $42.34 | 2021 | |
| Vericel Corporation | $25.75 | 2023 | Epicel (Cultured Epidermal Autografts) |
| Arbor Pharmaceuticals, INC. | $23.56 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.48 | 2023 | |
| Ascendis Pharma Endocrinology INC | $22.37 | 2025 | Yorvipath |
| Redhill Biopharma INC. | $16.64 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.50 | 2025 | Clenpiq |
| Astrazeneca Pharmaceuticals LP | $14.67 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.